Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23167627 | 1.00 | EPHX2 (0.44) | EPHX2RAB9AKMT2AL3MBTL1NAMPT | |
| SCHEMBL23167630 | 1.00 | EPHX2 (0.44) | EPHX2RAB9AKMT2AL3MBTL1NAMPT | |
| SCHEMBL23167123 | 0.92 | EPHX2 (0.39) | EPHX2RAB9AKMT2AL3MBTL1NAMPT | |
| SCHEMBL23167125 | 0.92 | EPHX2 (0.39) | EPHX2RAB9AKMT2AL3MBTL1NAMPT | |
| SCHEMBL18611965 | 0.85 | KDM1A (0.45) | EPHX2KMT2AL3MBTL1GRIN1GRIN2B | |
| SCHEMBL21996735 | 0.85 | KDM1A (0.45) | EPHX2KMT2AL3MBTL1GRIN1GRIN2B | |
| SCHEMBL18551550 | 0.85 | KDM1A (0.45) | EPHX2KMT2AL3MBTL1GRIN1GRIN2B | |
| SCHEMBL30182719 | 0.84 | KDM1A (0.56) | EPHX2RAB9AKMT2AL3MBTL1KDM1A | |
| SCHEMBL25136336 | 0.84 | KDM1A (0.56) | EPHX2RAB9AKMT2AL3MBTL1KDM1A | |
| SCHEMBL23951715 | 0.83 | PIK3CD (0.46) | EPHX2KMT2AL3MBTL1GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4110758-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | Tes Pharma S.r.l. (IT) | 2023-01-04 | — | — | EP | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | EPHX2 2416/4885RAB9A 3317/4885KMT2A 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.